Close

Pfizer establishes gene therapy unit for rare disease research

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Researchers at Washington University School of Medicine in St. Louis, US, have reported preliminary data from a small clinical trial of a new breast cancer vaccine.

Led by Washington University breast cancer surgeon and senior author Dr William Gillanders, the trial showed the vaccine to be safe in patients with metastatic breast cancer as well as helped slow cancer progression.

The new vaccine causes the body’s immune system to home in on a protein called mammaglobin-A, found almost in breast tissue.

Gillanders said: “Being able to target mammaglobin is exciting because it is expressed broadly in up to 80% of breast cancers, but not at meaningful levels in other tissues.
“The new vaccine causes the body’s immune system to home in on a protein called mammaglobin-A, found almost in breast tissue.”

“In theory, this means we could treat a large number of breast cancer patients with potentially fewer side effects.

“It’s also exciting to see this work progress from identifying the importance of mammaglobin-A, to designing a therapeutic agent, manufacturing it and giving it to patients, all by investigators at Washington University.”

The new vaccine primes a type of white blood cell, part of the body’s adaptive immune system, to seek out and destroy cells with the mammaglobin-A protein.

In the smaller proportion of breast cancer patients whose tumours do not produce mammaglobin-A, this vaccine would not be effective.

In the Phase I trial, 14 patients with metastatic breast cancer that expressed mammaglobin-A were vaccinated.

Gillanders said: “Despite the weakened immune systems in these patients, we did observe a biologic response to the vaccine while analysing immune cells in their blood samples.

“We also saw preliminary evidence of improved outcome, with modestly longer progression-free survival.”

Based on these results, Gillanders and his team are planning a larger clinical trial to test the vaccine in newly diagnosed breast cancer patients, who, in theory, should have more robust immune systems than patients who already have undergone extensive cancer therapy.

 

Latest stories

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back